Massive french study tracks Real-World use of diabetes drugs in over half a million patients

NCT ID NCT05882071

Ongoing Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study analyzes health records from over 547,000 people in France who started taking SGLT2 inhibitors for type 2 diabetes between 2020 and 2024. Researchers will describe patient characteristics, prescription patterns, and track the occurrence of heart attacks, strokes, heart failure, kidney problems, and safety events like ketoacidosis. The goal is to understand how these drugs are used in everyday practice and their real-world outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitors (a class of diabetes drugs)
What this could lead to: If successful, this study could help doctors understand how SGLT2 inhibitors are prescribed and their real-world effects on heart, kidney, and safety outcomes in people with type 2 diabetes.
What could go wrong: This is an observational study using existing health data, so it cannot prove cause and effect. Results may be influenced by factors not accounted for in the data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Boehringer Ingelheim

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.